CYP2C19 Reference Standard

Background

Clopidogrel is a new antiplatelet drug widely used in the fields of acute coronary syndrome, myocardial infarction, ischemic stroke, and peripheral arterial disease. Studies that have clearly established the relationship between CYP2C19 genotype and clopidogrel response have mainly focused on the field of acute coronary syndrome (ACS). There is a large body of evidence that CYP2C19 loss-of-function alleles (*2, *3) are associated with worse clinical symptoms. A large number of studies have shown that a similar relationship exists between CYP2C19 loss-of-function alleles and the indications for clopidogrel in the treatment of neurovascular diseases, such as acute ischemic stroke or TIA.